News

ProMetic and FDA Close Successful Pre-IND Meeting for PBI-4050 for Idiopathic Pulmonary Fibrosis

ProMetic Life Sciences, Inc., a biopharmaceutical corporation active in the development of novel therapeutic products targeting unmet medical needs in several fields, including fibrosis, is pleased to announce it recently concluded a successful Pre-Investigational New Drug (Pre-IND) meeting with the U.S. Food and Drug Administration (FDA) regarding its investigational anti-fibrotic…

Phase III Trials Reveal That IPF Patients Treated Continually with ESBRIET for Long-term Have Reduced Risk of Death

Results from phase III trials with Esbriet® (pirfenidone), a drug developed by Roche, were recently presented at the European Respiratory Society (ERS) congress held in Amsterdam from September 26-30, 2015. The results revealed that Esbriet® is beneficial for long-term treatment of idiopathic pulmonary fibrosis (IPF). Idiopathic pulmonary fibrosis is characterized by progressive…

New Insights into Exposure to Talc and Risk for Pulmonary Disease Talcosis

A team of researchers from The Netherlands recently discovered that talc (magnesium silicate), often used in the food industry, is a danger to health and exposure to it should be closely monitored. The study findings were recently presented by Dr. Jos Rooijackers, a pulmonologist from the Netherlands Expertise Centre for…

Long-Term IPF Treatment with OFEV® (Nintedanib) Shown to Remain Effective and Without New Safety Concerns

New data from the analysis of trial INPULSIS™-ON, describing the long-term efficacy and side-effects of OFEV in the treatment of idiopathic pulmonary fibrosis (IPF), was presented at the European Respiratory Society (ERS) International Congress 2015. IPF is a type of interstitial lung disease, affecting the tissue that supports the alveoli…

Improvements and Obstacles: How Is IPF Treatment Advancing?

Sixty-six year old Dan Castner was living life to the fullest when he started experiencing difficulties in breathing. While he worked in the outdoor industry for more than 40 years and was used to biking, climbing, camping, skiing and hiking, in March of 2012 his life completely changed. Castner was diagnosed with…

Researchers Discuss Idiopathic Pulmonary Fibrosis Comorbidities

A team of researchers from the Department of Clinical and Experimental Medicine at the University of Catania, Italy recently reviewed the co-occurrence of additional diseases in Idiopathic Pulmonary Fibrosis and their current therapeutic strategies. The study, entitled “IPF, comorbidities and management implications,“ was published in the Sarcoidosis Vasculitis and…